The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
Tesla, Inc.
TSLA · a US exchange · USD · Market cap $1.45T · 134,785 employees
Tesla, Inc.
PASS · Titan Ethical · score 80.1Price as of 15 Oct 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-10-15 · the tape above runs as of 15:23 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price362.44 USD at the 15 Oct 2026 close
- Our ratingAvoid, current read markdown
- Ethical screenPasses, score 80.1 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.58)
- Last reviewed15 Oct 2026 (4 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 362.44 against the desk's fair-value range, base estimate 215.46, over the last year.
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning political buying, disclosed 2026-09-25
- Options put/call open interest 0.58, read 2026-10-18
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Tesla, Inc. holds its Markdown at $362.44. Elevated stress, defensive posture warranted, held for 40 days.
| Phase | Markdown · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 40 days |
| Price at the screen | $362.44 |
| Valuation | 339.96 trailing · 168.43 forward price to earnings |
| Values screen | PASS · score 80.1 |
| Beta | 1.92 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 10.68% | Below 33% | Interest-bearing debt is just 10.7% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 19.99% | Below 33% | Cash held in interest-bearing accounts and securities is 20.0% of assets, under the one-third limit. | Pass |
| Receivables | 15.30% | Below 49% | Money owed to the company is 15.3% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.77% | Below 5% | Only 1.8% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Tesla, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 11%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-17. It updates when the underlying figures move, and past reads are kept below.
The Conscience OverlayThe quantitative screen above is arithmetic and this name passes it. Separately, community boycott lists cite this company: Documented on Ethical Consumer Boycotts List. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
The Fair Value Range
Our analysis reads AVOID: it trades above our $215.46 fair value estimate, weak competitive moat, 25.50% revenue growth.
Fair value range in USD, drawn from the 2026-10-15 screen. The gold marker is the market price at the same screen. The price runs 40.6% above the base estimate.
Third-party analyst targets: 38 covering, consensus Buy. The average target sits +14% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsTesla's Electric Ride Hits Cyclical Bump
Tesla's cars are as popular as ever, but the company's stock price is currently charging on the high side of reality. Despite the company's impressive 26% revenue growth, the stock is trading at a forward P/E ratio of 158.7x, which is far above the industry average. The reason it stands out as one to avoid is the combination of high valuation and the cyclical nature of the auto industry. Tesla's peak earnings and low multiple might seem like a bargain, but it's more of a warning sign of a potential cyclical value trap.
The risks are not just tied to valuation. Tesla's profit margin is a slim 4%, and a return on equity of just 5% doesn't inspire confidence. These figures are underpinned by a weak competitive moat, suggesting that while Tesla leads the electric vehicle market now, it may not be able to maintain its dominance as competitors catch up. The consensus rating of 'buy' from 40 analysts might seem reassuring, but their median target price of $415 is far from our fair value estimate of $216.69, indicating a potential disconnect between market optimism and underlying financials.
Tesla's ethical screen passes, which is a positive, but when considering the cyclical sector's pitfalls and the stock's stratospheric valuation, the prudent investor may want to keep their foot on the brake. This is particularly important as we consider the cyclical nature of the auto industry and the potential for earnings to drop in the next economic downturn.
Analysis, not advice.
| Forward P/E | 168.4xexpensive even after accounting for its growth |
| Trailing P/E | 340.0xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 1.08 |
| EPS, forward | 2.18 |
| Revenue growth | +25.5%strong top-line growth |
| Profit margin | 3.7%barely profitable |
| Return on equity | 4.7%a modest return on shareholder capital |
| FCF yield | 0.33% |
| Debt to equity | 0.18minimal debt: a conservative balance sheet |
| Current ratio | 1.94healthy short-term liquidity |
| Beta | 1.92much more volatile than the market |
| Short interest, float | 0.02% |
| 52-week range | 297.38 - 498.83 |
| Moat | WEAK |
| Market cap | $1.45T |
| Employees | 134,785 |
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeTSLA trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 9.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (41 analysts) rates it buy, with a mean price target of $412. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Elon Musk Says Optimus Is Tesla's Most Important Product. These 3 Suppliers Get Paid Before Tesla Does. Yahoo Finance · 1d ago
- 3 Founder Led Stocks With Up To 31% ROE Yahoo Finance · 2d ago
- Dow Jones Futures Loom After S&P 500, Nasdaq Break Support; Will Meta Earnings Save AI? Yahoo Finance · 2d ago
- Tesla (TSLA) Gets A Lift From China’s $37 Billion Subsidies And EV Tipping Point Yahoo Finance · 2d ago
- Rivian's Key to Success May Not Be Its Vehicles Yahoo Finance · 2d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-13 | Taneja Vaibhav | CFO | Sale | 3,000 | $1,350,000 |
| 2026-04-30 | Wilson-Thompson Kathleen | Dir | Sale | 26,409 | $9,985,390 |
| 2026-03-30 | Wilson-Thompson Kathleen | Dir | Sale | 25,809 | $9,273,888 |
| 2026-03-06 | Taneja Vaibhav | CFO | Sale | 2,265 | $899,077 |
| 2026-02-25 | Wilson-Thompson Kathleen | Dir | Sale | 25,731 | $10,692,814 |
| 2026-01-02 | Murdoch James R | Dir | Sale | 60,000 | $26,723,781 |
| 2025-12-09 | Musk Kimbal | Dir | Sale | 56,820 | $25,606,501 |
| 2025-12-08 | Taneja Vaibhav | CFO | Sale | 2,637 | $1,170,635 |
| 2025-09-15 | Murdoch James R | Dir | Sale | 60,000 | $25,360,800 |
| 2025-09-12 | Musk Elon | CEO, 10% | Purchase | 2,568,732 | $999,959,042 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | buy | 15K–50K |
| 2026-09-04 | Ro Khanna | Democrat | buy | 15K–50K |
| 2026-08-24 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-08-24 | Ro Khanna | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $445.00 | -14.3% | · | $858 | -14.3% |
| 2 months | $348.95 | +9.4% | · | $1,094 | +9.4% |
| 3 months | $395.01 | -3.4% | · | $966 | -3.4% |
| 6 months | $446.89 | -14.6% | · | $854 | -14.6% |
| 1 year | $326.09 | +17.0% | · | $1,170 | +17.0% |
| 2 years | $173.79 | +119.6% | · | $2,196 | +119.6% |
| 3 years | $244.40 | +56.1% | · | $1,561 | +56.1% |
| 5 years | $203.30 | +87.7% | · | $1,877 | +87.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TSLA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.